NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing
NurExone Biologic (OTCQB: NRXBF), a biopharmaceutical company focused on exosome-based regenerative therapies, announced several corporate updates. The company received a patent grant in Israel for "Production of Extracellular Vesicles from Stem Cells", complementing their recent U.S. patent allowance.
The company completed a non-brokered private placement raising C$632,655.68 through the issuance of 930,376 units at C$0.68 per unit. Each unit includes one common share and a half warrant exercisable at C$0.88 for 36 months. The proceeds will support preclinical pipeline and U.S. manufacturing initiatives.
Additionally, NurExone announced upcoming presentations at two major U.S. conferences: the 7th Annual Exosome-Based Therapeutic Development Summit and the Bioprocess International Conference in Boston, where company executives will showcase their ExoTherapy technology.
NurExone Biologic (OTCQB: NRXBF), una società biofarmaceutica focalizzata sulle terapie rigenerative basate su esosomi, ha annunciato diversi aggiornamenti societari. L'azienda ha ottenuto una concessione di brevetto in Israele per "Produzione di vescicole extracellulari da cellule staminali", che integra la recente concessione di un brevetto negli Stati Uniti.
La società ha completato un collocamento privato non assistito da broker che ha prodotto C$632,655.68 tramite l'emissione di 930,376 unità a C$0.68 per unità. Ogni unità comprende una azione ordinaria e un warrant parziale exercitabile a C$0.88 per 36 mesi. I proventi supporteranno la pipeline preclinica e le iniziative di produzione negli Stati Uniti.
Inoltre, NurExone ha annunciato presentazioni imminenti a due importanti conferenze statunitensi: il 7th Annual Exosome-Based Therapeutic Development Summit e la Bioprocess International Conference a Boston, dove i dirigenti dell'azienda esporranno la loro tecnologia ExoTherapy.
NurExone Biologic (OTCQB: NRXBF), una empresa biofarmacéutica centrada en terapias regenerativas basadas en exosomas, anunció varias actualizaciones corporativas. La empresa obtuvo una patente en Israel para "Producción de vesículas extracelulares a partir de células madre", complementando su reciente concesión de patente en EE. UU.
La compañía completó una colocación privada sin intermediación de brokers por un monto de C$632,655.68 mediante la emisión de 930,376 unidades a C$0.68 por unidad. Cada unidad incluye una acción común y un warrant parcial exercitable a C$0.88 por 36 meses. Los fondos respaldarán la cartera preclínica y las iniciativas de fabricación en EE. UU.
Además, NurExone anunció presentaciones próximas en dos importantes conferencias en EE. UU.: la 7th Annual Exosome-Based Therapeutic Development Summit y la Bioprocess International Conference en Boston, donde los ejecutivos de la empresa presentarán su tecnología ExoTherapy.
NurExone Biologic (OTCQB: NRXBF), 엑소좀 기반 재생 의약품에 집중하는 바이오제약 회사가 여러 기업 업데이트를 발표했다. 이스라엘에서 "줄기세포로부터의 세포외 소포체 생산"에 대한 특허를 취득했으며 이는 최근 미국 특허 허가를 보완한다.
회사는 브로커 없이 진행된 비공개 배정을 완료했고, C$632,655.68를 조달했으며 930,376주의 유닛을 C$0.68에 발행했다. 각 유닛에는 보통주 1주와 36개월 간 행사 가능한 반 매수권이 포함된다. 행사가는 C$0.88이다. 조달금은 전임상 파이프라인과 미국 제조 이니셔티브를 지원할 것이다.
또한 NurExone은 미국의 두 주요 학회에서 발표를 예고했다: 제7회 연차 Exosome-Based Therapeutic Development Summit와 보스턴에서 열리는 Bioprocess International Conference에서 경영진이 ExoTherapy 기술을 선보일 예정이다.
NurExone Biologic (OTCQB: NRXBF), une société biopharmaceutique axée sur les thérapies régénératives basées sur les exosomes, a annoncé plusieurs mises à jour d'entreprise. La société a obtenu un brevet en Israël pour « Production de vésicules extracellulaires à partir de cellules souches », complétant leur récente autorisation de brevet américaine.
La société a terminé un placement privé sans courtier levant C$632,655.68 par l'émission de 930,376 unités à C$0.68 par unité. Chaque unité comprend une action ordinaire et un warrant partiel exerçable à C$0.88 pendant 36 mois. Le produit des ventes soutiendra le pipeline préclinique et les initiatives de fabrication aux États-Unis.
De plus, NurExone a annoncé des présentations prochaines lors de deux grandes conférences américaines: le 7th Annual Exosome-Based Therapeutic Development Summit et la Bioprocess International Conference à Boston, où les dirigeants présenteront leur technologie ExoTherapy.
NurExone Biologic (OTCQB: NRXBF), ein biopharmazeutisches Unternehmen, das sich auf exosome-basierte regenerative Therapien konzentriert, hat mehrere Unternehmensaktualisierungen bekannt gegeben. Das Unternehmen erhielt eine Patentanmeldung in Israel für "Produktion von extrazellulären Vesikeln aus Stammzellen", was die jüngste US-Patentanmeldung ergänzt.
Das Unternehmen hat eine non-brokered private placement abgeschlossen und dabei C$632,655.68 durch die Emission von 930,376 Einheiten zu C$0.68 pro Einheit aufgenommen. Jede Einheit enthält eine Stammaktie und eine halbe Warrants, die zu C$0.88 für 36 Monate ausübbar ist. Die Mittel unterstützen die präklinische Pipeline und US-Herstellungsinitiativen.
Zusätzlich kündigte NurExone kommende Präsentationen bei zwei großen US-Konferenzen an: dem 7th Annual Exosome-Based Therapeutic Development Summit und der Bioprocess International Conference in Boston, wo Führungskräfte des Unternehmens ihre ExoTherapy-Technologie vorstellen werden.
NurExone Biologic (OTCQB: NRXBF)، شركة أدوية حيوية تركّز على العلاجات التجديدية القائمة على الإكسوسومات، أعلنت عن عدة تحديثات شركية. حصلت الشركة على منحة براءات اختراع في إسرائيل لـ"إنتاج الحويصلات خارج الخلية من الخلايا الجذعية"، وهو تكملة لإقرار براءة اختراعها الأمريكية الأخير.
أكملت الشركة طرحاً خاصاً غير وسيط جمع رأس مال بقيمة C$632,655.68 من خلال إصدار 930,376 وحدة بسعر C$0.68 للوحدة. كل وحدة تحتوي على سهم عادي و<>, يسمح بممارسة نصف warrants قابلة للمية لمدة 36 شهراً وبسعر تنفيذ C$0.88. ستدعم العوائد خط أنابيب ما قبل السريرية ومبادرات التصنيع في الولايات المتحدة.
بالإضافة إلى ذلك، أعلنت NurExone عن عروض تقديمية قادمة في اثنتين من أكبر المؤتمرات الأمريكية: قمة تطوير العلاجات المعتمدة على الإكوسومات السنوية السابعة و Bioprocess International Conference في بوسطن، حيث سيعرض كبار التنفيذيين في الشركة تقنيتهم ExoTherapy.
NurExone Biologic (OTCQB: NRXBF)，一家专注于基于外泌体的再生治疗的生物制药公司，宣布了多项公司更新。公司在以色列获得了“来自干细胞的细胞外囊泡生产”的专利授权，进一步补充了其最近的美国专利授权。
公司完成了一次非经纪人参与的私募融资，通过发行930,376份单位、单位价格为C$0.68，募集总额为
此外，NurExone宣布将在两场美国大型会议上进行演讲：第7届年度基于外泌体的治疗开发峰会以及在波士顿举行的生物工艺国际会议，届时公司高管将展示其ExoTherapy技术。
- Secured patent grant in Israel for exosome production technology
- Successfully raised C$632,655.68 through private placement for working capital
- Expanding presence through participation in major U.S. industry conferences
- Strategic manufacturing plans in U.S. through Exo-Top Inc. subsidiary
- Private placement subject to TSX Venture Exchange approval
- Shares issued in private placement subject to 4-month hold period
- Related party transaction involvement in the private placement
TORONTO and HAIFA, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a pioneering biopharmaceutical company developing exosome-based regenerative therapies, is pleased to provide the following corporate updates.
Israeli Patent Grant Expands Global Jurisdiction
The Israel Patent Office has granted the Company’s Patent, entitled “Production of Extracellular Vesicles from Stem Cells.” This grant aligns with NurExone’s recently announced U.S. Notice of Allowance for the same priority family of applications.
“While our clinical and commercial manufacturing of exosomes will be based in the U.S. through our Exo-Top Inc. subsidiary, expanding jurisdictional coverage further strengthens NurExone’s international intellectual property portfolio,” said Dr. Lior Shaltiel, CEO of NurExone.
Management Participation at U.S. Conferences
Dr. Ina Sarel, Head of CMC, Quality and Regulation, will present on NurExone’s exosome manufacturing platform at the 7th Annual Exosome-Based Therapeutic Development Summit in Boston, MA, a leading international meeting for exosome research and drug development. She will be co-hosting a fireside discussion entitled “Harmonizing the Exosome & Extra-Cellular Vesicle Regulatory Landscape Towards Better Definitions, Practices & Guidelines for Therapeutic Success.
Dr. Lior Shaltiel, CEO, will speak at the Bioprocess International Conference in Boston, MA, one of the largest global gatherings for biomanufacturing innovation. His presentation is entitled “From Antibodies to siRNA-Loaded Exosomes: AbbVie vs. NurExone in Advancing Spinal Cord Injury Treatments”.
These high-profile conferences provide opportunities for NurExone to showcase its proprietary ExoTherapy technology, expand U.S. presence, and engage potential partners and investors.
Private Placement
The Company is also pleased to announce that, subject to TSX Venture Exchange (“TSXV”) approval, it has closed a non-brokered private placement of 930,376 units (“Units”) at a price of C
“The completion of this financing provides incremental capital to support our preclinical pipeline and U.S. manufacturing initiatives,” said Eran Ovadya, CFO of NurExone. “It also positions us well as we prepare to accelerate our growth strategy.”
Terms of the Offering
Each Unit consisted of (i) one common share in the capital of the Company (each, a “Common Share”), and (ii) one-half of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share at a price of C
Closing of the Offering is subject to receipt of all necessary regulatory approvals, including the TSXV, and all securities issued under the Offering are subject to a statutory hold period of four months and one day from the closing of the Offering.
Related Party Transaction
Jay Richardson, a director of the Company, participated in the Offering and acquired 24,854 Units. The participation of Mr. Richardson in the Offering constituted a “related party transaction” and such term is defined in Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transaction (“MI 61-101”) and would have required the Company to receive minority shareholder approval for and obtain a formal valuation for the subject matter of the Offering in accordance with MI 61-101, prior to the completion of the Offering. However, in completing the Offering, the Company has relied on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of Mr. Richardson’s participation in the Offering as neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the Offering, insofar as it involved insiders, exceeded
The Offering was approved by the members of the board of directors of the Company who are independent for the purposes of the Offering insofar as it involved Mr. Richardson. No special committee was established in connection with the Offering.
Further details will be included in a material change report to be filed by the Company. The Company did not file a material change report more than 21 days before the closing date of the Offering as Mr. Richardson’s subscription was not known until closing and the subscribers requested to close the Offering in an expeditious manner. In the Company's view, the shorter period was necessary to permit the Company to close the Offering in a timeframe consistent with usual market practice for transactions of this nature and was reasonable in the circumstances.
About NurExone
NurExone Biologic Inc. is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar marketsi . Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.
For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
Allele Capital Partners
Investor Relations – U.S.
Phone: +1 978-857-5075
Email: aeriksen@allelecapital.com
FORWARD-LOOKING STATEMENTS
This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: clinical and commercial manufacturing of the Company’s exosomes will be based in the U.S.; Dr. Sarel and Dr. Shaltiel presenting in the upcoming events as outlined herein; Dr. Sarel co-hosting a fireside discussion as outlined herein; the Company expanding its U.S. presence and engaging potential partners and investors; the Company receiving all regulatory approvals, including TSXV approval, for the Offering; the use of proceeds from the Offering; long-term protection of the Company’s intellectual property and manufacturing process; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.
These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company’s clinical and commercial manufacturing of exosomes will be based in the U.S.; Dr. Sarel and Dr. Shaltiel will present in the upcoming events as outlined herein; Dr. Sarel will co-host a fireside discussion as outlined herein; the Company will expand its U.S. presence and engage potential partners and investors; the Company will receive all regulatory approvals, including TSXV approval, for the Offering; the Company will use the proceeds from the Offering as outlined herein; the Company will have long-term protection of its intellectual property and manufacturing process; and the NurExone platform technology will offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company’s clinical and commercial manufacturing of exosomes will not be based in the U.S.; Dr. Sarel and/or Dr. Shaltiel will not present in the upcoming events as outlined herein; Dr. Sarel will not co-host a fireside discussion as outlined herein; the Company will not expand its U.S. presence and/or engage potential partners and/or investors; the Company will not receive all required regulatory approvals, including TSXV approval; the Company will not use the proceeds from the Offering as outlined herein; government regulation; the Company’s early stage of development; lack of revenues to date; the inherent uncertainty of preclinical drug development, including the risk that product candidates may not advance to clinical trials or receive regulatory approval; the possibility that results from preclinical studies and early-stage trials may not predict later outcomes; the uncertain timing, cost, and outcome of preclinical and clinical development activities; risks related to the clinical trial process, including potential delays or failure to achieve effective trial design or positive results; the inability to obtain or maintain required regulatory approvals; limited market acceptance of the Company’s products, even if approved; the potential emergence of competing therapies that are safer, more effective, or more affordable; rapid technological change that may impact the relevance of the Company’s technologies; the Company’s dependence on key personnel and strategic partners; the inability to obtain adequate financing; risks related to the Company’s ability to protect its intellectual property; the possibility that the Company’s technologies, including its exosome-based platforms, may not achieve their intended therapeutic impact; the inability to produce or scale exosome-based products for clinical use; limited adoption in regenerative medicine or cell therapy applications; lack of growing clinical demand in targeted indications such as spinal cord injury, optic nerve repair, or other therapeutic areas; failure to meet planned development milestones or achieve commercial breakthroughs; the Company’s inability to have long-term protection of its intellectual property and/or manufacturing process; the Company’s exosomes will be not be regenerative; the Company will be unable to launch first-in-human clinical trials; the Company and Exo-Top Inc. will be unable to advance into clinical and/or commercial phases, launch commercial-scale production and/or business-to-business exosome supply, achieve scalability and/or advance their manufacturing methods; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications; and the risks discussed under the heading “Risk Factors” on pages 44 to 51 of the Company’s Annual Information Form dated August 27, 2024, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
i Spinal cord injury, Glaucoma
FAQ
What is the recent patent granted to NurExone Biologic (NRXBF) in Israel?
How much did NurExone Biologic raise in their recent private placement?
What are the terms of NurExone's private placement warrants?
Where will NurExone be presenting their ExoTherapy technology?
How will NurExone use the proceeds from the private placement?
